Melinta Therapeutics, Inc. (MLNT) financial statements (2021 and earlier)

Company profile

Business Address 44 WHIPPANY ROAD
MORRISTOWN, NJ 07963
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 821282321549997
Cash and cash equivalents 821282321549997
Restricted cash and investments 00    
Receivables (0)86822
Inventory, net of allowances, customer advances and progress billings 4111   
Inventory 4111    
Prepaid expense  21130
Other undisclosed current assets 260    
Total current assets: 14915023816210599
Noncurrent Assets
Property, plant and equipment 220000
Intangible assets, net (including goodwill) 2298   
Intangible assets, net (excluding goodwill) 2298    
Deposits noncurrent assets   0000
Other noncurrent assets 611    
Total noncurrent assets: 292110000
TOTAL ASSETS: 44216023916210599
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 55322313158
Accounts payable 1771610126
Accrued liabilities 34243110
Employee-related liabilities   4221
Interest and dividends payable 40  0 
Debt   7442
Derivative instruments and hedges, liabilities      1
Deferred revenue and credits    0
Other undisclosed current liabilities 78   (0) 
Total current liabilities: 1343230181811
Noncurrent Liabilities
Long-term debt and lease obligation 110409151513
Long-term debt, excluding current maturities 110409151513
Liabilities, other than long-term debt 7171711116
Deferred revenue and credits101711116
Other liabilities 77    
Total noncurrent liabilities: 1185626272618
Total liabilities: 2528855444429
Stockholders' equity
Stockholders' equity attributable to parent 190721831186170
Common stock 000000
Additional paid in capital 910645620437289236
Accumulated deficit (720)(573)(437)(319)(228)(166)
Total stockholders' equity: 190721831186170
TOTAL LIABILITIES AND EQUITY: 44216023916210599

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues 96341827158
Revenue, net341822158
Cost of revenue
(Cost of Goods and Services Sold)
 (41)     
Gross profit: 55341827158
Operating expenses (255)(113)(135)(116)(75)(51)
Other undisclosed operating income 41     
Operating loss: (158)(79)(117)(89)(59)(43)
Nonoperating income (expense) 120(1)(2)(2)(2)
Other nonoperating income (expense) 120(1)(2)(2)(2)
Interest and debt expense (46)(4)(1)(0)(2)(2)
Net loss: (203)(63)(119)(91)(64)(47)
Other undisclosed net income attributable to parent 4641022
Net loss attributable to parent: (157)(59)(118)(91)(62)(45)
Other undisclosed net loss available to common stockholders, basic  (19)    
Net loss available to common stockholders, diluted: (157)(78)(118)(91)(62)(45)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss: (203)(63)(119)(91)(64)(47)
Comprehensive loss, net of tax, attributable to parent: (203)(63)(119)(91)(64)(47)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: